Nantcell, Inc.

Mezmo Corporation

Immunitybio, Inc.

Nantkwest Inc.

John H Lee

Hans G Klingemann

Laurent H Boissel

Kayvan R Niazi

Jeffrey Safrit

Wonjae Cha

Patrick Soon-Shiong

Jong Oh Choi

Nathan T Schomer

Sungho Lee

Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

HIV treatment compositions and methods

A captioned telephone service (CTS) system for blocking spam calls includes a CTS server and a database. A CTS user's equipment is associated with a CTS number and an original phone number. The CTS server is configured to allow the user to elect to use an original number service and a call drop service. If the original number service is set, when the user places a phone call to a peer by using the CTS number, the original phone number, instead of the CTS number, is displayed as caller identification on a communications device of the peer. The CTS server assists the user to set up call forwarding and checks whether the call forwarding was successfully set. If the call drop service is set, the CTS server drops a call, directed to the CTS number. However, emergent calls or emergency related calls are excluded from the call drop service.

Captioned telephone service system for providing original number service and anti-spam function

A recombinant natural killer (NK) cell or T-cell composition is transfected with a nucleic acid encoding i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and/or iv) a secreted immune modulator selected from a TGFβ inhibitor and/or IL-12, where the recombinant cell is gamma (γ)-irradiated conferring inhibition of cell proliferation with transient activity of the transfected molecules including the secreted immune modulators for up to 72 hours.

Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment

A system for centralized captioned telephone service ('C-CTS'), which includes a C-CTS system (“C-CTSS”) for providing a transcription service to a user subscribed to the C-CTS during a phone call with a peer; a mobile communications device of the user which includes a first phone number assigned from a carrier of the user; a communications device of the peer which includes a second phone number; and a plurality of caption providers that communicate with the C-CTSS. The first phone number is associated with the C-CTSS and each of the caption providers provides a captioned telephone service. A carrier of the first phone number includes a voice network, a data network, and a database that stores the first phone number of the user which is subscribed to the C-CTS. The C-CTSS includes a database that stores the first phone number of the user.

System for centralized captioned telephone service

A captioned telephone service system having the text-to-speech and answer assistance functions includes a captioner, a text-to-speech system, and an answer assistance system. The captioner provides captions to a user during a phone call between the user and a peer by receiving the peer's voice from a peer device, transcribing the peer's voice into caption data, and transferring the caption data to the user device. The text-to-speech system is configured to receive text data from the user device, convert the text data into speech, and transfer the voice of the speech to the peer device via the voice path in real time. The answer assistance system is configured to receive the caption data from the captioner, analyze the caption data to identify a question, analyze the question to generate answer suggestions, and forward the answer suggestions to the user device for review, editing, and selection.

Captioned telephone service system having text-to-speech and answer assistance functions

A system for identifying spoken language in a telecommunications relay service, which includes a call serving entity; and a plurality of automatic speech recognition groups where each of the automatic speech recognition groups includes an associated automatic speech recognition engine that recognizes and transcribes speech to a predefined language. One of the plurality of automatic speech recognition groups is set as a default automatic speech recognition group and automatic speech recognition engines transcribe and convert peer voices into text packets. The text packets are scored by the automatic speech recognition engine and transmitted to the call serving entity to determine whether the text packets meet a predetermined threshold based on their respective scores with the text packet having the highest score that meets or exceeds the predetermine threshold transmitted to a user.

System and method for identifying spoken language in telecommunications relay service

Methods and pharmaceutical combinations for preventing, reducing the occurrence of, and/or treating an infection in a subject are provided herein. The method includes administering to the subject a therapeutically effective amount of an IL-15 agonist after or concomitantly with administration of a therapeutically effective amount of an antibiotic to the subject. The pharmaceutical combination includes an IL-15 agonist and an antibiotic.

IL-15 agonist drug combinations for immune therapy

Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of Fc&#x3b5;RI&#x3b3; and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

Provided herein are modified NK-92&#xae; cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92&#xae; cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92&#xae; cells, as well as methods of treating cancer using the modified cells.

Growing community of inventors

Culver City, CA, United States of America

John H Lee